Last --
Change Today 0.00 / 0.00%
Volume 0.0
4166 On Other Exchanges
4166 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

orient pharma co ltd (4166) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ORIENT PHARMA CO LTD (4166)

Related News

No related news articles were found.

orient pharma co ltd (4166) Related Businessweek News

No Related Businessweek News Found

orient pharma co ltd (4166) Details

Orient PHARMA Co., Ltd. is engaged in the research and development, and manufacture of drugs. Its product portfolio includes GlucoMet, a tablet for type II diabetes; Sonimax, a capsule for insomnia; Mycros, a capsule for hypertension; Immufine, a capsule for rejection in organ transplantation; Kytron, an injection for nausea and vomiting associated with cancer chemotherapy or radiotherapy; and Lafuzo, a tablet for benigh prostatic hyperplasia. The company also provides various research and development technologies; product registration or other services; clinical study related services to conduct multi-nation and multi-center early phase clinical studies; and OEM and contract development services. In addition, it is involved in the development of various products for sialorrhoea, tuberculosis, and attention deficit hyperactivity disorders. The company was founded in 2008 and is based in Taipei, Taiwan. Orient PHARMA Co., Ltd. is a subsidiary of Orient Europharma Co., Ltd.

Founded in 2008

orient pharma co ltd (4166) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

orient pharma co ltd (4166) Key Developments

Orient Pharma Co., Ltd., Annual General Meeting, Jun 12, 2014

Orient Pharma Co., Ltd., Annual General Meeting, Jun 12, 2014.

DURECT Corporation Announces Selection with Orient Pharma Co. of Lead Formulation for ORADUR(R)-Methylphenidate

DURECT Corporation announced that it and its collaborator Orient PHARMA Co. Ltd. have selected a lead formulation for the lead program in DURECT's ORADUR-ADHD program, ORADUR-Methylphenidate. This lead formulation was chosen based on its potential for rapid onset of action, long duration with once-a-day dosing and target pharmacokinetic profile as demonstrated in a recent Phase 1 trial. In addition, this product candidate will utilize a small capsule size relative to the leading existing long acting products on the market and incorporates DURECT's ORADUR anti-tampering technology. Orient PHARMA is planning to meet with the Taiwan Food and Drug Administration (TFDA) later this year to discuss the Phase 3 program in that market and is developing its plans for further development in the defined Asian and South Pacific countries to which it has rights from DURECT. DURECT retains rights to all other markets in the world, notably including the U.S., Europe and Japan, and is initiating licensing discussions with other companies now that the lead formulation has been selected.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4166:TT 39.69 TWD +0.33

4166 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4166.
View Industry Companies

Industry Analysis


Industry Average

Valuation 4166 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 34.6x
Price/Book 5.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 33.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ORIENT PHARMA CO LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at